LENZ Therapeutics, Inc. (LENZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.96+2.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LENZ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -46.8% |
| Our one-year growth estimate | diamond | 41.8% |
Growth built into the price is above our model estimate.
The price assumes 88.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LENZ — officer change
Dated 2026-07-02
Director — Zach Scheiner: Dr. Zach Scheiner resigned from the Board of Directors and all committees without a named successor.
Why it matters: Getting regulatory approvals can open new markets. This can help increase revenue.
Supportive ifApproval of VIZZ in at least one new international market by Q4 2026.
Worry ifNo regulatory approvals for VIZZ in new markets by Q4 2026.
Why it matters: Expanding the sales force is key. It helps increase market reach and product sales.
Supportive ifSales force is fully deployed by the end of Q2 2026, enhancing ECP engagement.
Worry ifSales force expansion is delayed past Q2 2026. This limits market penetration.
Why it matters: Another earnings miss would worry people about the company’s ability to meet goals. This may hurt investor confidence.
Worry ifQ2 earnings report shows a loss greater than previous earnings misses.
Less concerning ifQ2 earnings report shows a profit or loss smaller than previous misses.
Why it matters: This report will show how revenue is growing. It will also cover operational losses.
Watch forThe earnings report shows smaller operating losses. They are less than $44.1 million in Q1 2026.
Also watch forThe earnings report shows operating losses are worse. They are more than $44.1 million.
Why it matters: If the health care sector grows faster, it could help LENZ improve its performance. This is crucial for its future.
Supportive ifHealth care sector revenue growth rises back toward 10% or higher.
Worry ifHealth care sector revenue growth continues to slow below 10%.
Why it matters: Growth in product revenue will show if the launch of VIZZ is gaining traction. This is key for LENZ's future.
Supportive ifIn Q2 2026, product revenue is over $2 million. This shows strong market adoption.
Worry ifQ2 2026 product revenue stays below $1.9 million, suggesting weak demand.
Why it matters: High adoption rates through telehealth can boost VIZZ sales and patient access.
Supportive ifOver 30% of new VIZZ prescriptions come from the telehealth channel within three months.
Worry ifLess than 10% of new prescriptions originate from the telehealth channel in the same period.
Why it matters: Managing losses is key for financial health. Improvement shows better cost control.
Supportive ifOperating losses decrease from $44.1 million in Q1 2026 to below $40 million in Q2 2026.
Worry ifLosses rise above $44.1 million in Q2 2026. This shows worsening financial health.
Why it matters: A new board member can mean changes in strategy. This can affect investor trust.
Watch forA new board member is announced within the next quarter.
Also watch forNo announcement of a new board member occurs in the next quarter.
Why it matters: A new board member can mean changes in strategy or management. This affects stability.
Watch forA new board member is appointed to replace Dr. Zach Scheiner.
Also watch forNo new board member is chosen. This may show possible instability.
Why it matters: Growing revenue shows that the market is accepting the product. It supports management's launch plan.
Supportive ifQ3 revenue from VIZZ product sales exceeds $5.5 million.
Worry ifQ3 revenue from VIZZ product sales falls below $5.5 million.
Why it matters: Controlling SG&A costs is key. It helps lower losses and improves financial health.
Worry ifSG&A expenses decrease below $39.4 million in Q3.
Less concerning ifSG&A expenses increase above $39.4 million in Q3.
Why it matters: Success in the telehealth channel could drive more patients to adopt VIZZ, boosting sales.
Supportive ifThe telehealth channel filled over 10,000 prescriptions in Q3.
Worry ifThe telehealth channel filled fewer than 5,000 prescriptions in Q3.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$280 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $754 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,064 loss on $10,000 · 90.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.